nevirapine has been researched along with rilpivirine in 49 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (8.16) | 29.6817 |
2010's | 34 (69.39) | 24.3611 |
2020's | 11 (22.45) | 2.80 |
Authors | Studies |
---|---|
Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P | 1 |
Andries, K; Arnold, E; Bettens, E; Daeyaert, FF; Das, K; de Béthune, MP; de Jonge, MR; Gaurrand, S; Guillemont, J; Heeres, J; Hertogs, K; Janssen, PA; Koymans, LM; Lewi, PJ; Palandjian, P; Pasquier, E; Pauwels, R; Timmerman, P; Vernier, D; Vinkers, MH; Wigerinck, P | 1 |
Bettens, E; Demestre, C; Guillemont, J; Heeres, J; Hertogs, K; Lewi, P; Masungi, C; Mordant, C; Pasquier, E; Peeters, A; Queguiner, L; Schmitt, B; Smeulders, L | 1 |
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Azijn, H; Boven, K; de Béthune, MP; Jochmans, D; Kraus, G; Picchio, G; Rimsky, LT; Tirry, I; Van Craenenbroeck, E; Vingerhoets, J | 1 |
Anderson, KS; Bollini, M; Domaoal, RA; Gallardo-Macias, R; Jorgensen, WL; Spasov, KA; Thakur, VV | 1 |
Anderson, KS; Bollini, M; Gallardo-Macias, R; Jorgensen, WL; Spasov, KA; Tirado-Rives, J | 1 |
Chen, FE; Daelemans, D; De Clercq, E; Liu, Y; Ma, XD; Pannecouque, C; Yang, S | 1 |
Anderson, KS; Arnold, E; Bauman, JD; Bollini, M; Cisneros, JA; Das, K; Frey, KM; Jorgensen, WL; Spasov, KA | 1 |
Anderson, KS; Bollini, M; Cisneros, JA; Jorgensen, WL; Spasov, KA | 1 |
Balzarini, J; Chen, W; De Clercq, E; Liu, H; Liu, X; Pannecouque, C; Rai, D; Zhan, P; Zhou, Z | 1 |
Anderson, KS; Bollini, M; Frey, KM; Gallardo-Macias, R; Jorgensen, WL; Lee, WG; Spasov, KA | 1 |
Elgaher, WA; Hartmann, RW; Haupenthal, J; Mély, Y; Pires, M; Real, E; Saladini, F; Sharma, KK | 1 |
Jorgensen, WL | 1 |
Devale, TL; Miniyar, P; Murumkar, P; Parikh, J; Sharma, P; Shrivastava, B | 1 |
Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H | 1 |
Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P | 1 |
Daelemans, D; De Clercq, E; Kang, D; Liu, X; Pannecouque, C; Tian, Y; Wang, Z; Yu, Z; Zhan, P; Zhang, J | 1 |
Anderson, KS; Frey, KM; Gannam, ZTK; Jorgensen, WL; Kudalkar, SN; Lee, WG; Sasaki, T; Spasov, KA | 1 |
Arnold, E; De Clercq, E; Fang, Z; Feng, D; Kang, D; Liu, X; Pannecouque, C; Pilch, A; Ruiz, FX; Sun, Y; Wang, Z; Wei, F; Zhan, P; Zhao, T | 1 |
Anderson, KS; Bertoletti, N; Carter, ZJ; Cisneros, JA; Cutrona, KJ; Ippolito, JA; Jin, S; Jorgensen, WL; Niu, H; Spasov, KA; Valhondo, M | 1 |
Arnold, E; De Clercq, E; Feng, D; Gao, S; Jing, L; Kang, D; Liu, X; Pannecouque, C; Ruiz, FX; Sun, L; Sun, Y; Wang, Z; Zhan, P; Zhang, T | 1 |
Chen, FE; De Clercq, E; Ding, L; Pannecouque, C; Zhuang, C | 3 |
Cherukupalli, S; De Clercq, E; Jia, R; Jiang, X; Kang, D; Liu, X; Pannecouque, C; Wang, W; Wang, Z; Xie, M; Zhan, P | 1 |
Chen, FE; De Clercq, E; Huang, WJ; Jin, X; Pannecouque, C; Wang, S; Zhang, YX; Zhao, LM | 1 |
Chen, FE; Clercq, E; Hao, QQ; Ling, X; Pannecouque, C | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S | 1 |
Giaquinto, C; Penazzato, M | 1 |
Davis, PH; Minkara, MS; Radhakrishnan, ML | 1 |
Balamane, M; Fessel, WJ; Katzenstein, DA; Melikian, GL; Shafer, RW; Varghese, V | 1 |
El-Nahal, WG; Monroe, JI; Shirts, MR | 1 |
Colby-Germinario, SP; Han, Y; Huang, W; Oliveira, M; Petropoulos, CJ; Quan, Y; Wainberg, MA; Xu, HT | 1 |
Back, D; Kaye, S; Khoo, S; Mackie, NE; Mora-Peris, B; Vera, JH; Waldman, AD; Watson, V; Weston, R; Winston, A | 1 |
Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V | 1 |
Crawford, KW | 1 |
Blonk, M; Burger, D; Rijnders, BJ; Rokx, C; Verbon, A | 1 |
Aboulker, JP; Charreau, I; de Castro, N; Delaugerre, C; Gallien, S; Mahjoub, N; Molina, JM; Nere, ML; Simon, F | 1 |
Camacho, RJ; Gomes, P; Rhee, SY; Theys, K; Vandamme, AM | 1 |
Hannongbua, S; Ishii, K; Kato, K; Thammaporn, R; Uchiyama, S; Yagi-Utsumi, M | 1 |
Avihingsanon, A; Mekprasan, S; Ohata, PJ; Putcharoen, O; Ruxrungtham, K; Sirivichayakul, S; Teeranaipong, P | 1 |
Diphoko, T; Essex, M; Gaseitsiwe, S; Kasvosve, I; Makhema, J; Marlink, R; Moyo, S; Musonda, R; Novitsky, V; Okatch, H; Wainberg, M | 1 |
Abraham, OC; Demosthenes, JP; Ghale, BC; Kannangai, R; Ramalingam, VV; Rupali, P; Varghese, GM | 1 |
Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
Barnard, JP; Huber, KD; Sluis-Cremer, N | 1 |
Choengpanya, K; Choowongkomon, K; Kiriwan, D; Lamtha, T; Rattanabunyong, S; Rattanasrisomporn, J; Shaikh, AR; Suwattanasophon, C; Wolschann, P | 1 |
3 review(s) available for nevirapine and rilpivirine
Article | Year |
---|---|
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Genome, Viral; HIV; HIV Infections; Humans; Interdisciplinary Communication; Models, Molecular; Molecular Structure; Mutation; Nitriles; Pyrimidines; Rilpivirine | 2005 |
Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
Topics: Acetamides; Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Prodrugs; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2019 |
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2011 |
3 trial(s) available for nevirapine and rilpivirine
Article | Year |
---|---|
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine | 2011 |
The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
Topics: HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Prospective Studies; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Viral Load | 2015 |
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Retreatment; Reverse Transcriptase Inhibitors; Rilpivirine; Young Adult | 2015 |
43 other study(ies) available for nevirapine and rilpivirine
Article | Year |
---|---|
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2005 |
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Female; HIV-1; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Nitriles; Pyrimidines; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rilpivirine; Spectrophotometry, Ultraviolet | 2007 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Molecular Structure; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine | 2010 |
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
Topics: Anti-HIV Agents; Catechols; Computer Simulation; Ethers; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Stereoisomerism; T-Lymphocytes | 2011 |
Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
Topics: Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Benzophenones; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
Topics: Anti-HIV Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Molecular Structure; Pyrimidines; Solubility; Structure-Activity Relationship | 2013 |
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cell Proliferation; Dose-Response Relationship, Drug; HIV-1; Humans; Hydrazines; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Solubility; Structure-Activity Relationship | 2013 |
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
Topics: Anti-HIV Agents; Crystallization; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
Topics: | 2014 |
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Carboxylic Acids; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Escherichia coli; HEK293 Cells; HeLa Cells; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Thiophenes | 2016 |
Computer-aided discovery of anti-HIV agents.
Topics: Anti-HIV Agents; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; T-Lymphocytes | 2016 |
Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Isatin; Molecular Docking Simulation; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2017 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles | 2018 |
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2019 |
Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Catechols; Drug Design; HIV Reverse Transcriptase; Molecular Structure; Reverse Transcriptase Inhibitors | 2019 |
Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
Topics: Animals; Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Drug Discovery; ERG1 Potassium Channel; Female; Fluorine; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Microsomes, Liver; Molecular Structure; Protein Binding; Pyrimidines; Rats, Wistar; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiophenes | 2020 |
Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
Topics: | 2021 |
2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Drug Design; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Microbial Sensitivity Tests; Molecular Structure; Mutation; Protein Binding; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
Topics: Alkylation; Animals; Binding Sites; Biphenyl Compounds; Cell Line; Cell Survival; Drug Design; Drug Stability; Female; Half-Life; HIV Reverse Transcriptase; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Microsomes, Liver; Molecular Docking Simulation; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
Topics: Animals; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
Topics: Animals; Anti-HIV Agents; Binding Sites; Cell Survival; Cytochrome P-450 Enzyme System; Drug Design; Drug Resistance, Viral; Drug Stability; Female; Half-Life; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Molecular Docking Simulation; Mutation; Pyridines; Pyrimidines; Solubility; Structure-Activity Relationship | 2022 |
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2022 |
Structure-Based Discovery of Novel NH
Topics: Anti-HIV Agents; Biphenyl Compounds; Drug Design; Heterocyclic Compounds, 1-Ring; HIV Reverse Transcriptase; HIV-1; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2022 |
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2022 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load | 2011 |
Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.
Topics: Alkynes; Benzoxazines; Binding Sites; Cyclopropanes; HIV Reverse Transcriptase; Mutation; Nevirapine; Nitriles; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Static Electricity | 2012 |
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2012 |
Investigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations.
Topics: HIV Reverse Transcriptase; Models, Molecular; Molecular Dynamics Simulation; Mutation; Nevirapine; Nitriles; Principal Component Analysis; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2014 |
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2013 |
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal Fluid; Drug Substitution; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Pyrimidines; Rilpivirine; Semen; Viral Load | 2014 |
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Organophosphonates; Prospective Studies; Pyrimidines; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Treatment Outcome; Viral Load | 2014 |
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Rilpivirine; Treatment Failure | 2015 |
Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Reverse Transcriptase; Mass Spectrometry; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2016 |
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Thailand; Viral Load; Young Adult | 2016 |
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Nevirapine; Nitriles; pol Gene Products, Human Immunodeficiency Virus; Prevalence; Pyridazines; Pyrimidines; Rilpivirine; Treatment Failure; Young Adult | 2018 |
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sweden | 2019 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |
Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Fluorescence Polarization; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Rilpivirine | 2019 |
Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
Topics: Animals; Anti-HIV Agents; Cat Diseases; Cats; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Nevirapine; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |